申请人:The Noguchi Institute
公开号:EP2354790A1
公开(公告)日:2011-08-10
The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determinied in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(-)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determinied in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(-)), and benign prostatic hyperplasia is determined in the case of 30% or less.
本发明提供了一种快速、高灵敏度地检测前列腺特异性抗原(PSA)的聚糖结构并根据该结构的差异判断前列腺癌的方法,特别是一种准确判断前列腺癌和良性前列腺增生的方法。一种确定前列腺癌的方法,其中该方法包括一个步骤,即分析来自测试对象的样本中的 PSA 聚糖结构、如果具有 LacdiNAc(N-乙酰半乳糖胺-N-乙酰葡糖胺)(LacdiNAc(+))的聚糖的量超过不具有 LacdiNAc 但具有 LacNAc(半乳糖-N-乙酰葡糖胺)(LacdiNAc(-))的聚糖的量的 30%,则可确定前列腺癌。特别是一种用于确定前列腺癌的方法,其中在具有 LacdiNAc(N-乙酰半乳糖胺-N-乙酰葡糖胺)(LacdiNAc(+))的聚糖的量超过不具有 LacdiNAc 但具有 LacNAc(半乳糖-N-乙酰葡糖胺)(LacdiNAc(-))的聚糖的量的 30% 的情况下确定前列腺癌,而在 30% 或以下的情况下确定良性前列腺增生。